Takeda, Bayer e terapias avançadas: quando uma porta se fecha, outra se abre
When one door closes, another opens — and sometimes in the same week.
While Takeda announced its exit from cell therapy R&D, citing strategic refocus, Bayer moved in the opposite direction — claiming a world first by advancing both a cell therapy and a gene therapy for Parkinson’s disease into late-stage clinical development.
Bayer’s bemdaneprocel (pluripotent stem cell–derived dopaminergic neurons) is now in Phase III, while its gene therapy AB-1005 (encoding GDNF) advances in Phase II — both targeting the neurodegeneration that defines Parkinson’s.
This divergence between two pharma giants illustrates a fundamental truth:
Cell and gene therapies are not a single race — they are multiple marathons, each requiring unique science, infrastructure, and long-term commitment.
Takeda’s exit reminds us how difficult it is to scale cell therapy innovation sustainably. Bayer’s progress, on the other hand, highlights the growing maturity of advanced therapy ecosystems — from manufacturing networks to regulatory frameworks and the cold chain that connects labs to patients.
Whether through withdrawal or acceleration, both moves help redefine where the field stands today — on the edge between scientific possibility and commercial reality.
#bayer #cryopraxis #cellpraxis #cellandgenetherapy #stemcell #bionk #bemdaneprocel
Perguntas frequentes
- O que a Takeda anunciou em terapia celular?
- A saída da pesquisa e desenvolvimento em terapia celular, justificada por reposicionamento estratégico.
- O que a Bayer está desenvolvendo para Parkinson?
- O bemdaneprocel, neurônios dopaminérgicos derivados de células-tronco pluripotentes em Fase III, e a terapia gênica AB-1005 (que codifica GDNF), em Fase II.
- O que esses movimentos opostos indicam?
- Que terapias celulares e gênicas não são uma corrida única, mas várias maratonas — cada uma com ciência, infraestrutura, cadeia de frio e compromisso de longo prazo próprios.